Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-01 7:23 pm Purchase | 13G | IBIO INC PAR $0.001 IBIO | Lynx1 Capital Management LP | 878,492 9.99% | 878,492 (New Position) | View |
| 2024-03-29 4:15 pm Purchase | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 4,845,871 8.7% | 4,466,712 (+1178.06%) | View |
| 2024-02-16 4:57 pm Purchase | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 2,994,059 5.8% | 2,994,059 (New Position) | View |
| 2024-02-14 09:22 am Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Lynx1 Capital Management LP | 3,813,926 6.6% | 687,753 (+22.00%) | View |
| 2024-02-14 09:21 am Sale | 13G | KINNATE BIOPHARMA INC KNTE | Lynx1 Capital Management LP | 1,997,006 4.2% | -216,172 (-9.77%) | View |
| 2024-02-14 09:21 am Sale | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 379,159 0.7% | -2,976,758 (-88.70%) | View |
| 2024-02-14 09:21 am Purchase | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 3,134,396 6.4% | 12,177 (+0.39%) | View |
| 2024-02-14 09:20 am Purchase | 13G | STOKE THERAPEUTICS INC STOK | Lynx1 Capital Management LP | 2,956,918 6.6% | 292,760 (+10.99%) | View |
| 2024-02-14 09:20 am Sale | 13G | CABALETTA BIO INC CABA | Lynx1 Capital Management LP | 2,139,644 4.99% | -686,332 (-24.29%) | View |
| 2024-02-14 09:19 am Purchase | 13G | PIERIS PHARMACEUTICALS INC PIRS | Lynx1 Capital Management LP | 9,775,849 9.9% | 4,147,264 (+73.68%) | View |
| 2024-02-14 09:19 am Sale | 13G | NEOLEUKIN THERAPEUTICS INC NLTX | Lynx1 Capital Management LP | 46 0.1% | -2,291,087 (-100.00%) | View |
| 2024-02-14 09:18 am Sale | 13G | BIONOMICS LTD ADS BNOX | Lynx1 Capital Management LP | 148,374,900 7.8% | -6,400,800 (-4.14%) | View |
| 2023-11-13 4:55 pm Purchase | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 3,122,219 6.3% | 3,122,219 (New Position) | View |
| 2023-11-06 4:55 pm Purchase | 13G | STOKE THERAPEUTICS INC STOK | Lynx1 Capital Management LP | 2,664,158 6% | 2,664,158 (New Position) | View |
| 2023-10-30 4:21 pm Purchase | 13G | BIONOMICS LTD ADS BNOX | Lynx1 Capital Management LP | 154,775,700 8.2% | 154,775,700 (New Position) | View |
| 2023-06-02 4:56 pm Purchase | 13G | TSCAN THERAPEUTICS INC TCRX | Lynx1 Capital Management LP | 5,224,600 12.2% | 5,224,600 (New Position) | View |
| 2023-02-14 4:07 pm Purchase | 13G | CABALETTA BIO INC CABA | Lynx1 Capital Management LP | 2,825,976 9.7% | 465,664 (+19.73%) | View |
| 2023-02-14 4:06 pm Purchase | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 3,355,917 6.2% | 603,495 (+21.93%) | View |
| 2023-02-14 4:06 pm Purchase | 13G | PIERIS PHARMACEUTICALS INC PIRS | Lynx1 Capital Management LP | 5,628,585 7.6% | 1,803,966 (+47.17%) | View |
| 2023-02-14 4:05 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Lynx1 Capital Management LP | 3,126,173 6.8% | 1,588,828 (+103.35%) | View |